GERMANTOWN, Maryland, November 13 /PRNewswire/ --

On October 26, 2007, WestChina-Frontier PharmaTech, also known as the National Chengdu Center for Safety Evaluation of Drugs (NCCSED), received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. AAALAC is an internationally recognized, not-for-profit organization, which promotes the humane treatment of animals in science through voluntary accreditation and assessment programs.

As a result of an extensive on-site evaluation, AAALAC determined that the WestChina-Frontier PharmaTech possesses state-of-the-art facilities and industry-leading programs for the care and use of laboratory animals. In addition, AAALAC noted the following in its official approval letter: that "the (company has) extensive administrative support and commitment to high standards throughout the program; the well designed and implemented training program; the genuine and deep sense of collegiality among personnel within the program at all levels' the excellent Institutional animal Care and Use Committee (IACUC) process with good documentation; the special arrangements to allow outdoor exercise for dogs; (as well as) the attention to detail in the areas of sanitation and general orderliness of facilities".

"The outcome of this AAALAC site visit demonstrates the excellent collaboration efforts between NCCSED and our partner, Frontier BioSciences. While this accreditation is not a regulatory requirement, it is an important validation of the quality, responsiveness, and the credibility of our research work", said Dr. Li Wang, CEO and Director of WestChina-Frontier PharmaTech. "The AAALAC accreditation comes as a result of our efforts to improve core operational infrastructure and service capabilities. With ongoing investments in infrastructure and world class personnel, Frontier and its partners are continuously committed to quality, responsiveness, reliability, and the satisfaction of our clients' expectations", commented by Dr. Dong Xie, President of Frontier.

About Frontier BioSciences and WestChina-Frontier PharmaTech Co Ltd.

Frontier BioSciences, Inc. is a Maryland-based company that partners with WestChina-Frontier PharmaTech Co Ltd. in Chengdu, China, providing a full spectrum of drug discovery and development resources to biotechnology and pharmaceutical industries in the scientific disciplines of GLP-compliant toxicology, developmental and reproductive toxicology, pharmacology, genetic toxicology, pathology, analytical chemistry, and international regulatory guidance.

Recent investment at the Chengdu facility resulted in the recent implementation of Pathology Data Systems (PDS), which includes comprehensive and GLP-certified data capture and FDA-compliant reporting module. In response to increasing demand for study placement, expansion plans are also underway early next year for the build-out of an additional 100,000 square-foot facility, adjacent to the current facility, with 31 new small animal rooms and 34 large animal rooms, increasing testing capacity by almost 200%.

Web site: http://www.frontierbsi.com

Beth Wong, AVP, Business Development of Frontier BioSciences, Inc., +1-301-251-0231, +1-240-372-2100, bwong@frontierbsi.com